ClinicalTrials.gg
CompletedNCT01999517CoNaNUpdated Oct 29, 2019Results posted

Contrast Nephropathy and Nitrates

A Phase 4 interventional study of Intravenous Nitroglycerin and IV Fluids in Contrast Induced Nephropathy, sponsored by Mt. Sinai Medical Center, Miami. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.

Sponsored by Mt. Sinai Medical Center, Miami · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Contrast-induced nephropathy (CIN) is a complication of percutaneous coronary angiography that occurs in about 10 to 20% of patients exposed to contrast media. Iodinated contrast is used during coronary angiography to see the coronary arteries. It has been shown that exposure to this agent may cause kidney injury. CIN usually goes away on its own but in some high risk patients it progresses into renal failure.

This research study offers a new possible option to prevent CIN. We propose that if intravenous nitroglycerin is given before the procedure it may lower the chances of developing contrast-induced nephropathy.

Read the detailed description

The Contrast Nephropathy and Nitrates trial (CoNaN) is a single center, randomized, 1 x 1 factorial clinical trial designed to test the effects of intravenous nitroglycerin infusion in renal function given prior to PCI.

Specific aims for this trial include:

  • To determine whether the intravenous nitrates have any effect on the glomerular filtration rate (GFR) after the exposure to contrast media.
  • To determine if intravenous nitroglycerin will decrease the incidence of contrast induced Nephropathy.

    400 patients with a Mehran score of > 6 and a pre-procedural creatinine measurement will be enrolled. Following baseline assessments, patients will be randomly assigned to receive intravenous infusion nitroglycerine plus intravenous normal saline or normal saline only. Subjects will participate in this study from the time they sign consent (prior to angiographic procedure), until 48-72 hours post procedure.

02

Conditions studied

  • Contrast Induced Nephropathy
03

In context

Lead sponsor

Mt. Sinai Medical Center, Miami is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be scheduled for percutaneous coronary angiography.
  2. Patients must have a Mehran score more or equal to 6 before the procedure.
  3. Patients must have baseline creatinine and hemoblogin drawn before the procedure.
  4. Signed .

Exclusion criteria

Exclusion Criteria:

  1. Patients on renal replacement therapy before randomization, will be excluded.
  2. Being exposed to any types of nitrates 48 hours prior to randomization,
  3. History of allergic reaction to any of the components of intravenous nitroglycerin.
  4. Exposure to contrast media 4 days prior randomization.
  5. Planned revascularization in the next 24 to 48 hours of the first PCI procedure.
  6. The patient is hypotensive (\<90/60mmHg) at the time of randomization.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
122 participants (actual)

Study arms

  • Active comparator
    Intravenous Nitroglycerin

    IV Nitroglycerin with IV Fluids

    Drug: Intravenous Nitroglycerin · Drug: IV Fluids

  • Placebo comparator
    Placebo

    IV Fluids

    Drug: IV Fluids

Interventions

06

What researchers measure

Primary outcomes

  1. Change in GFR

    The primary endpoint for this trial will be to determine the change in glomerular filtration rate after exposure to contrast media. We will compare the change in GFR before and after PCI of the group that received intravenous nitroglycerin with the change in GFR before and after PCI of the group that did not receive intravenous nitroglycerin.

    Time frame: Baseline and 48 to 72 hours post-PCI

07

Results

Posted Oct 29, 2019

Participant flow

Participant flow — Overall Study
MilestoneIntravenous NitroglycerinPlacebo
Started6854
Completed6854
Not completed00

Outcome measures

PrimaryChange in GFR

The primary endpoint for this trial will be to determine the change in glomerular filtration rate after exposure to contrast media. We will compare the change in GFR before and after PCI of the group that received intravenous nitroglycerin with the change in GFR before and after PCI of the group that did not receive intravenous nitroglycerin.

Time frame:
Baseline and 48 to 72 hours post-PCI
Reported as:
Median · mL/min
Change in GFR
mL/minIntravenous NitroglycerinPlacebo
Change in GFR1.8 (-5.9 to 6.9)-4.1 (-9.3 to 3)

Adverse events

Collected over 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravenous Nitroglycerin0/68 (0%)0/68 (0%)4/68 (5.9%)
Placebo0/54 (0%)0/54 (0%)2/54 (3.7%)
Most frequent other events
Most frequent other events
EventIntravenous NitroglycerinPlacebo
HypotensionCardiac disorders4/682/54

Baseline characteristics

122 patients consented for participation, met all inclusion/exclusion criteria and were analyzed in the intention-to-treat protocol.

Age, Continuous
Age, Continuous(years)Intravenous NitroglycerinPlaceboTotal
Median77 (69.5 to 82)76 (68 to 85)76 (69 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)Intravenous NitroglycerinPlaceboTotal
Female161632
Male523890
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Intravenous NitroglycerinPlaceboTotal
Race/Ethnicity — White262147
Race/Ethnicity — Black538
Race/Ethnicity — Asian224
Race/Ethnicity — Hispanic342761
Race/Ethnicity — Unknown/not reported112
Region of Enrollment
Region of Enrollment(Participants)Intravenous NitroglycerinPlaceboTotal
United States6854122
eGFR (Baseline)
eGFR (Baseline)(mL/min)Intravenous NitroglycerinPlaceboTotal
Median58.3 (43.7 to 78.5)59.1 (48.5 to 77.6)58.6 (46.7 to 77.9)
08

Study locations

1 site
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Jun 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2013
First posted
Dec 3, 2013
Start
Jun 2013
Primary completionActual
Jun 2018
CompletionActual
Jun 2018
Results first posted
Oct 29, 2019
Last update
Oct 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01999517
Lead sponsor
Mt. Sinai Medical Center, Miami
Collaborators
Florida Heart Research Institute
Responsible party
Gervasio Lamas, MD (Chied of Medicine, Chair of Cardiology, Mt. Sinai Medical Center, Miami) — Principal investigator
First posted
Dec 3, 2013
Start date
Jun 2013
Primary completion
Jun 2018
Completion
Jun 2018
Results posted
Oct 29, 2019
Last update
Oct 29, 2019

Study contacts

Gervasio Lamas, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitroglycerin

Start the discussion